Clinical Read2026-06-15

TALVEY (talquetamab-tgvs) plus DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) - (MonumenTAL-3)

Johnson & JohnsonJNJ
Indication
Relapsed or refractory multiple myeloma
Stage
phase3
Event
Phase 3